Merck CEO: Don't Judge All Pharma On Turing
This article was originally published in Scrip
Executive Summary
While it was rumored the Obama administration was ready to unveil some sort of administrative action to rein in drug costs at an invitation-only Nov. 20 forum that brought biopharmaceutical makers together with payers, employers, consumer and patient advocates, health care providers and other stakeholders, no such rule, regulation or guideline was revealed.